Breast cancer management is becoming increasingly biology-driven, with treatment decisions extending well beyond anatomic stage and conventional receptor classification.

Across systemic therapy, surgery and radiation oncology, emerging evidence is refining how clinicians characterize tumor biology, identify treatment resistance and determine which patients may safely avoid components of therapy.

The common direction is toward greater therapeutic precision: selecting treatment according to molecular features and response while limiting toxicity when additional intervention is unlikely to improve outcomes.

Reshma Mahtani, D.O., medical oncologist at Baptist Health Herbert Wertheim Cancer Institute and chief of breast medical oncology at Baptist Health Wellness and Medical Complex, and Mehran Habibi, M.D., surgical breast oncologist, chief of breast surgery at Wertheim Cancer Institute and deputy chief of breast surgery for Baptist Health Cancer Care, discuss several 2026 developments with potential implications for clinical practice.

“The most important shift is toward precision treatment, using tumor biology and response to therapy to determine not only what treatment a patient needs, but also what treatment she may safely avoid,” Dr. Habibi says.

Antibody-Drug Conjugates Move Earlier in the Treatment Course

Antibody-drug conjugates (ADCs) remain one of the most active areas of breast cancer therapeutics. By linking a tumor-directed antibody to a cytotoxic payload, these agents are designed to increase delivery of chemotherapy to cells expressing a specific target.

“Antibody drug conjugates act like targeted delivery systems, using an antibody to recognize a protein on the cancer cell and deliver a potent chemotherapy payload more directly to the tumor,” Dr. Mahtani explains.

In 2026, she says, ADCs continued moving into earlier disease settings and earlier lines of therapy, including in triple-negative and HER2-positive breast cancer. Their expanding use also underscores the need to characterize tumors beyond broad histologic categories and traditional stage.

“‘Breast cancer’ is not one disease; even tumors that appear identical under the microscope can behave very differently at the molecular level,” Dr. Habibi says. “Genomic and molecular profiling allows us to understand the biology driving an individual cancer.”

As treatment options become increasingly biomarker-dependent, that molecular definition may influence systemic therapy from the outset and may also affect downstream surgical and radiation decisions.

ctDNA and the Prospect of Detecting Resistance Before Radiographic Progression

Circulating tumor DNA (ctDNA) is also moving closer to the clinical decision-making pathway. These tumor-derived DNA fragments can provide a serial, blood-based view of molecular change during treatment and may identify emerging resistance before progression is apparent on conventional imaging.

One closely watched 2026 study, SERENA-6, demonstrated that an emerging ESR1 mutation could be detected in blood and used to trigger a change in endocrine therapy before radiographic progression, with a resulting delay in disease progression.

“Blood-based ctDNA testing is beginning to give us a more dynamic picture of how a breast cancer is changing over time,” Dr. Mahtani says.

For metastatic disease, the clinical appeal is clear: treatment may eventually be adapted to evolving tumor biology rather than waiting for an anatomic change to become visible. In early-stage disease, however, the potential role of ctDNA is more complex.

Dr. Habibi notes that increasingly sensitive assays can sometimes detect molecular evidence of recurrence months—and potentially years—before disease becomes clinically apparent. The unresolved issue is whether acting on that signal improves patient outcomes.

“If we can identify molecular recurrence that early, the critical question now is whether intervening at that stage can prevent or delay metastatic disease,” he says.

De-escalation: Defining When Less Treatment Is Appropriate

Another major research direction is de-escalation: identifying patients for whom omission of a treatment component preserves oncologic outcomes while reducing morbidity.

Dr. Habibi points to studies suggesting that selected patients who respond to preoperative chemotherapy may be able to avoid regional lymph-node radiation, while some women with small, clinically node-negative tumors may not require sentinel lymph-node surgery.

These approaches depend on careful patient selection rather than broad treatment reduction.

“De-escalation does not mean undertreating cancer,” he says. “It means eliminating treatments that do not add meaningful benefit for a particular patient.”

A similar principle is being tested in systemic therapy. Dr. Mahtani highlights the OPTIMA study, which found that genomic testing could help identify some patients with clinically high-risk, node-positive, estrogen receptor-positive, HER2-negative early breast cancer who could safely avoid chemotherapy.

The clinical objective is not simply to reduce treatment intensity, but to preserve disease control while minimizing acute toxicity and long-term treatment burden.

From Stage-Based Care to Integrated Biologic Risk

Taken together, these developments illustrate how breast cancer management is shifting from a predominantly stage-based framework toward an integrated assessment of tumor biology, genomic risk, treatment response and molecular evolution.

Two patients with the same tumor size, nodal status and traditional subtype may appropriately receive different management based on HER2 expression, actionable mutations, PD-L1 status, genomic risk, response to neoadjuvant therapy or evidence of resistance detected in blood.

“We are already there in many respects,” Dr. Habibi says. “Two patients with the same tumor size and stage may appropriately receive very different systemic therapy, and increasingly different surgery and radiation.”

That increasing complexity also raises the value of multidisciplinary review. As systemic therapy moves earlier, molecular testing becomes more consequential and de-escalation strategies become more selective, coordination among medical oncology, breast surgery, radiation oncology, pathology, radiology and genetics becomes increasingly important to sequence care appropriately.

At the same time, advances in precision treatment do not diminish the importance of screening and early diagnosis. “We are making real progress against breast cancer,” Dr. Mahtani says. “Early detection still matters enormously because finding a cancer at an earlier stage can significantly improve the chance of cure.”

The next phase of breast cancer care is therefore likely to be defined not by simply adding more therapy, but by using increasingly precise biologic information to determine which treatment is needed, when it should be delivered and when it can safely be omitted.